The prognostic value of Phosphorylated AKT expression in non-small cell lung cancer: A meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Qiu, Zhi Xin ^a   Zhang, Kui ^b   Qiu, Xue Song ^c   Zhou, Min ^d   Li, Wei Min ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Yubei District People's Hospital   (China)

^d Infectious Disease Control and Prevention Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; ENZYME PHOSPHORYLATION; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84891917101     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081451     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. doi:10.3322/canjclin. 55.2.74. PubMed: 15761078. (Pubitemid 40372904)
2. Wang J, Wang B, Chen X, Bi J (2011) The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 32:411-416. doi:10.1093/carcin/bgq266. PubMed: 21156971.
3. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501. doi:10.1038/nrc839. PubMed: 12094235. (Pubitemid 37328931)
4. Coffer PJ, Jin J, Woodgett JR (1998) Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335(1):1-13. PubMed: 9742206. (Pubitemid 28477043)
5. Staal SP (1987) Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 84:5034-5037. doi:10.1073/pnas.84.14. 5034. PubMed: 3037531. (Pubitemid 17095859)
6. Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS et al. (2002) Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8:1100-1106. PubMed: 12006525. (Pubitemid 34517646)
7. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR (1998) Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 21:81-86. doi:10.1002/(SICI) 1098-2744 (199802) 21:2. PubMed: 9496907. (Pubitemid 28122842)
8. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T et al. (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171. PubMed: 11948129. (Pubitemid 35177371)
9. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321. doi:10.1126/science.282.5392.1318. PubMed: 9812896. (Pubitemid 28524494)
10. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868. doi:10.1016/S0092-8674 (00) 80595-4. PubMed: 10102273. (Pubitemid 29165088)
11. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605. doi:10.1038/21224. PubMed: 10376603.
12. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N et al. (2002) Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 62:2971-2975. PubMed: 12019180. (Pubitemid 34525787)
13. Zhang K, Wang XQ, Zhou B, Zhang L (2013) The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a metaanalysis. Fam. Cancer.
14. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834. doi:10.1002/(SICI) 1097-0258 (19981230) 17:24. PubMed: 9921604. (Pubitemid 28562978)
15. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826. doi: 10.7326/0003-4819-127-9- 199711010-00008. PubMed: 9382404. (Pubitemid 27465551)
16. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a metaanalysis. Stat Med 21:1539-1558. doi:10.1002/sim.1186. PubMed: 12111919.
17. David O, Jett J, LeBeau H, Dy G, Hughes J, et al. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stageindependent survival disadvantage. Clin Cancer Res 10:6865-6871. (Pubitemid 39383035)
18. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E et al. (2004) Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133-1141. doi: 10.1093/jnci/djh217. PubMed: 15292385. (Pubitemid 39207049)
19. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ et al. (2005) Phospho-akt expression is associated with a favorable outcome in nonsmall cell lung cancer. Clin Cancer Res 11:2930-2936. doi: 10.1158/1078-0432. CCR-04-1385. PubMed: 15837744. (Pubitemid 40525195)
20. Tsurutani J, Steinberg SM, Ballas M, Robertson M, LoPiccolo J et al. (2007) Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 55:115-121. doi:10.1016/j.lungcan. 2006.09.026. PubMed: 17097759. (Pubitemid 46038882)
21. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ et al. (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16:240-248. doi:10.1158/1078- 0432. CCR-09-0986. PubMed: 20008839.
22. Pu R, Li WM, Liu D, Mo XM, Tang Y et al. (2010) The expression and clinical significance of AKT2, phosphorylated AKT2 in non-small cell lung cancer. Sichuan da Xue Xue Bao Yi Xue Ban 41:586-589. PubMed: 20848774.
23. Liu D, Huang Y, Chen B, Zeng J, Guo N et al. (2011) Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer 117:3763-3773. doi:10.1002/cncr.25959. PubMed: 21387259.
24. An SJ, Lin QX, Chen ZH, Su J, Cheng H et al. (2012) Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with nonsmall cell lung cancer. Exp Ther Med 4:226-230. PubMed: 23139712.
25. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ et al. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59:2551-2556. PubMed: 10363971. (Pubitemid 29269096)
26. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ (2001) Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21:2203-2212. doi:10.1128/MCB.21.6.2203-2212.2001. PubMed: 11238953. (Pubitemid 32479640)
27. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276:9817-9824. doi:10.1074/jbc. M010840200. PubMed: 11139588.
28. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C et al. (1998) The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 58:5239-5247. PubMed: 9823338. (Pubitemid 28521188)
29. Brognard J, Clark AS, Ni Y, Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997. PubMed: 11358816. (Pubitemid 32720961)
30. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N et al. (2003) Increased phospho-AKT (Ser (473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12:660-664. PubMed: 12869408. (Pubitemid 36899849)
31. Horiguchi A, Oya M, Uchida A, Marumo K, Murai M (2003) Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169:710-713. doi:10.1016/S0022-5347 (05) 63998-5. PubMed: 12544348. (Pubitemid 36133028)
32. Pérez-Tenorio G, Stål O (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545. doi:10.1038/sj.bjc.6600126. PubMed: 11870534. (Pubitemid 34185089)
33. Cheng YH, Zhang CF (2011) Clinical significance of EGFR gene mutations and Expression of Downstream Phosphorylated Signal Transduction Proteins AKT and ERK protein expression in Non-Small Cell Lung Carcinoma. Master's degree thesis